CTRI/2020/10/028556
Active, not recruiting
Phase 4
A, multicentre, prospective, open labeled phase IV study to evaluate safety andefficacy of Dienogest in patients suffering from endometriosis
Jagsonpal Pharmaceuticals Limited0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: N809- Endometriosis, unspecified
- Sponsor
- Jagsonpal Pharmaceuticals Limited
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients with a confirmed diagnosis of Endometriosis based on laparoscopy or
- •2\.Patients who receive a prescription of DIENOGEST according to the
- •indication stated in the local approved SmPC.
- •3\.Written informed consent signed by the patient or legally acceptable
- •representative(s) in line with applicable re.gulation of country.
- •4\.Planned treatment in line with the Summary of Product Characteristics, i.e.
- •exclusion of all patients with contraindications.
Exclusion Criteria
- •1\.Exclusion of all patients with contraindications as per Investigators discretion
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 4
Adapalene 0.3% - Benzoyl peroxide 2.5% gel in subjects with Moderate to Severe Acne VulgarisHealth Condition 1: L700- Acne vulgarisCTRI/2021/06/034069GALDERMA India Pvt Ltd
Recruiting
Phase 4
A prospective phase IV studyto evaluate safety and efficacy profile of DenosteRel® in post-menopausal women with osteoporosisHealth Condition 1: M810- Age-related osteoporosis without current pathological fractureCTRI/2024/03/064638Reliance Life Sciences Pvt Ltd RLS
Active, not recruiting
Phase 4
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as Infimabâ?¢ in patients with moderate to severe plaque psoriasis which is a skin disease characterized by raised red patches covered with a silvery white buildup of dead skincells or scaleHealth Condition 1: L400- Psoriasis vulgarisCTRI/2019/09/021078Reliance Life Sciences Pvt Ltd
Completed
Phase 4
The post marketing clinical research on drug Infliximab in patients with moderate to severe Crohn’s diseaseHealth Condition 1: K509- Crohns disease, unspecifiedHealth Condition 2: null- Patients with moderate to severe Crohn’s diseaseCTRI/2018/03/012298Reliance Life Sciences Pvt Ltd100
Active, not recruiting
Phase 4
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as AdaliRel�® in patients with moderate to severe plaque psoriasis which is a skin disease characterized by raised red patches covered with a silvery white buildup of dead skin cells or scaleHealth Condition 1: L400- Psoriasis vulgarisCTRI/2019/10/021694Reliance Life Sciences Pvt Ltd RLS